ANNX Fundamental Analysis - ANNEXON INC

Fundamental Rating

Overall ANNX gets a fundamental rating of 3 out of 10. We evaluated ANNX against 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANNX as it has an excellent financial health rating, but there are worries on the profitability. ANNX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ANNX had negative earnings in the past year.

In the past year ANNX has reported a negative cash flow from operations.

In the past 5 years ANNX always reported negative net income.

In the past 5 years ANNX always reported negative operating cash flow.

1.2 Ratios

ANNX's Return On Assets of -55.24% is in line compared to the rest of the industry. ANNX outperforms 46.28% of its industry peers.

ANNX has a Return On Equity (-68.66%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-55.24%
ROE	-68.66%
ROIC	N/A

ROA(3y)-44.79%

ROA(5y)-39.91%

ROE(3y)-54.04%

ROE(5y)-47.75%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANNX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANNX has more shares outstanding

ANNX has less shares outstanding than it did 5 years ago.

There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ANNX has an Altman-Z score of -1.87. This is a bad value and indicates that ANNX is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of ANNX (-1.87) is comparable to the rest of the industry.

There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.87

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 7.99 indicates that ANNX has no problem at all paying its short term obligations.

With a decent Current ratio value of 7.99, ANNX is doing good in the industry, outperforming 70.24% of the companies in the same industry.

A Quick Ratio of 7.99 indicates that ANNX has no problem at all paying its short term obligations.

ANNX has a better Quick ratio (7.99) than 70.42% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.99
Quick Ratio	7.99

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.73% over the past year.

EPS 1Y (TTM)19.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-76.19%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ANNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.12% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-45.29%

EPS Next 2Y-19.4%

EPS Next 3Y4.92%

EPS Next 5Y31.12%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ANNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANNX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-19.4%

EPS Next 3Y4.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ANNX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANNEXON INC

NASDAQ:ANNX (8/4/2025, 8:00:00 PM)

After market: 2.53 0 (0%)

2.53

+0.08 (+3.27%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2025-05-12/bmo

Earnings (Next)08-18 2025-08-18

Inst Owners96.19%

Inst Owner Change-0.74%

Ins Owners0.57%

Ins Owner Change-4.58%

Market Cap277.57M

Analysts84.29

Price Target11.83 (367.59%)

Short Float %10.28%

Short Ratio6.47

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-21.28%

Min EPS beat(2)-22.39%

Max EPS beat(2)-20.16%

EPS beat(4)2

Avg EPS beat(4)-8.96%

Min EPS beat(4)-22.39%

Max EPS beat(4)5.28%

EPS beat(8)6

Avg EPS beat(8)6.77%

EPS beat(12)9

Avg EPS beat(12)9.04%

EPS beat(16)10

Avg EPS beat(16)5.9%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-18.31%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-19.81%

EPS NY rev (1m)0%

EPS NY rev (3m)-15.62%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.14
P/tB	1.14
EV/EBITDA	N/A

EPS(TTM)-1.18

EYN/A

EPS(NY)-1.45

Fwd EYN/A

FCF(TTM)-1.28

FCFYN/A

OCF(TTM)-1.27

OCFYN/A

SpS0

BVpS2.22

TBVpS2.22

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-55.24%
ROE	-68.66%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-44.79%

ROA(5y)-39.91%

ROE(3y)-54.04%

ROE(5y)-47.75%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	4.14%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.99
Quick Ratio	7.99
Altman-Z	-1.87

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)106.39%

Cap/Depr(5y)92.98%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)19.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-76.19%

EPS Next Y-45.29%

EPS Next 2Y-19.4%

EPS Next 3Y4.92%

EPS Next 5Y31.12%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-39.57%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-65.93%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-16.11%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-17.46%

OCF growth 3YN/A

OCF growth 5YN/A

ANNEXON INC (ANNX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens